Mathias Jucker

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia

Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease

The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease

Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease

The prion principle and Alzheimer’s disease

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer’s disease

Alzheimer's disease: From immunotherapy to immunoprevention

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease

Medin co-aggregates with vascular amyloid-β in Alzheimer’s disease

Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition

Autosomal dominant and sporadic late onset Alzheimer's disease share a common<i>in vivo</i>pathophysiology

Experimental evidence for temporal uncoupling of brain Aβ deposition and neurodegenerative sequelae

Signatures of glial activity can be detected in the CSF proteome

Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life

Potential human transmission of amyloid β pathology: surveillance and risks

Systematic review of guidelines for internal validity in the design,conduct and analysis of preclinical biomedical experiments involvinglaboratory animalsSystematic review of guidelines for internal validity inthe design, conduct and analysis of preclinical biomedical experimentsinvolving laboratory animals

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

Cryo-EM structure and polymorphism of Aβ amyloid fibrils purified from Alzheimer’s brain tissue

An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations

Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease